Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
about
Epigenetics as a mechanism driving polygenic clinical drug resistanceMethylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylationMucins: a new family of epigenetic biomarkers in epithelial cancers.Intergenic, gene terminal, and intragenic CpG islands in the human genome.5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromesIdentification of novel methylation markers in hepatocellular carcinoma using a methylation arrayCancer chemoprevention by dietary polyphenols: promising role for epigenetics.Methylation of the SLC6a2 gene promoter in major depression and panic disorderInterstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitorDown-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Promoter Hypermethylation Profiling Identifies Subtypes of Head and Neck Cancer with Distinct Viral, Environmental, Genetic and Survival CharacteristicsPreclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancerHighly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.Epigenetics: an emerging technology in the diagnosis and treatment of cancer.Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.Epigenetic aberrations and cancer.Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer.Cytostatic drug treatment causes seeding of gene promoter methylation.Drug resistance and the role of combination chemotherapy in improving patient outcomes.Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasisUncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma.Real-time colorimetric detection of DNA methylation of the PAX1 gene in cervical scrapings for cervical cancer screening with thiol-labeled PCR primers and gold nanoparticles.DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators.The application of delivery systems for DNA methyltransferase inhibitors.Structure, function, and epigenetic regulation of BNIP3: a pathophysiological relevance.Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.Investigating the antiviral role of cell death-inducing DFF45-like effector B in HCV replication.Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas.Epigenetic dysregulation in cancer.DNA methylation reduces binding and cleavage by bleomycin.MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays.Methylated BNIP3 gene in colorectal cancer prognosis.DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinomaCan the state of cancer chemotherapy resistance be reverted by epigenetic therapy?Genomic structure, transcriptional control, and tissue distribution of HERG1 and KCNQ1 genes.DNMT3B (C46359T) polymorphisms and immunoexpression of DNMT3b and DNMT1 proteins in oral lichen planus.Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.
P2860
Q24651640-C88F730C-1628-45C8-8062-0DF8EA32A2F6Q24682832-6E5EB55E-2234-475A-9906-15F8F48DAA53Q30597703-BBCD93F1-5D9E-45A1-8884-D2FCE1140A5DQ33525172-B580FA7E-8C42-4439-AA04-3B3ED257B523Q33665187-E3B0D84D-A7D5-4CB3-A2DC-863A4630F17AQ33876297-62FC0621-DC59-4892-B39B-AE5F4F4B0CFDQ34014744-A3F2B75C-D213-48A4-A240-3AEDAFFCDB13Q34279875-DF87DB7D-0BD4-4F75-B74C-3B871EAB0E35Q35061589-725FA4F1-7A67-457C-ADD0-131504BF5B0AQ35136616-BDDA748A-5BD7-4548-A938-E28FB623C009Q35176131-A23C4FE6-568B-4746-A962-4DCF5A9F7BB1Q35233239-ADF9F181-A8EB-4B2F-A946-70C808BE8B07Q35670835-014B2BD4-62BC-453F-B5B8-19EA6A94D4C5Q35739684-9985C0B7-1E30-4A70-92A1-A12B06B1CED8Q36081416-A94C2A44-9637-4A21-8086-D2924213FEDCQ36517999-AD2EC271-C9BD-4F5A-BB94-1C00FABFD345Q36555927-D3862273-D2BB-4FE7-BC64-03605A608BC4Q36609590-596C7ED2-CA4B-4B29-A147-8F3E1CB7DBABQ36648081-80C81C2C-181D-4CA0-9991-73B3F0E6BDC2Q36667464-3EFABB56-F03C-4F05-83F1-7EBEED1E764CQ36725766-D01C4AC6-4637-4BE0-973B-DB7994734257Q36999509-66AB1048-9DFC-4144-8A6F-D4B2F12E3A4CQ37014726-07C414D5-6C08-4897-B9A0-F121C3B60367Q37219171-D90D7A34-60BD-4067-AF19-48AB0AE7482CQ37347224-4F2CA8F4-0F83-42EB-A093-D3974B42DEA6Q37873228-CFA661DB-7030-403E-9480-1236B0B384F5Q37911496-E490EC02-6CBA-476E-8E3B-9228BE3240A0Q38237290-9C527F13-5639-482C-A743-7D58FED65D7FQ38697331-7A7EBFED-382A-49BC-9A70-E9DA929AF833Q38979549-141C5617-B454-447E-A8DB-84584B5937C6Q39149024-3001AB74-9AD4-4A97-961C-F196B980C2AEQ39950903-5A598EC2-E195-497B-89FB-8B3CCB093A7AQ41890596-AC21B050-C17C-4DF5-9871-47C8E6419F25Q41965853-376CA9E1-A763-408D-9D21-459AC0507C51Q42323760-BBA91CA9-10E7-4A6F-801E-2D5E70F0E099Q42370578-6366D4BE-37A6-4113-9733-0170E49ACCCDQ42584531-F0CFD641-55E2-4413-9DCE-DB89687CDDFBQ42642223-64EE88ED-0D67-45CB-9936-7406FD704F2FQ43682595-7BF1DBC5-2B13-443C-90BD-9992D33C2679Q45814103-BE02C595-7614-4242-9577-4BB71B6679A2
P2860
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Epigenetic silencing mediated ...... tic target and as a biomarker.
@ast
Epigenetic silencing mediated ...... tic target and as a biomarker.
@en
type
label
Epigenetic silencing mediated ...... tic target and as a biomarker.
@ast
Epigenetic silencing mediated ...... tic target and as a biomarker.
@en
prefLabel
Epigenetic silencing mediated ...... tic target and as a biomarker.
@ast
Epigenetic silencing mediated ...... tic target and as a biomarker.
@en
P2093
P1476
Epigenetic silencing mediated ...... tic target and as a biomarker.
@en
P2093
Gordon Strathdee
Jens M Teodoridis
Robert Brown
P304
P356
10.1016/J.DRUP.2004.06.005
P577
2004-08-01T00:00:00Z